Summary
Clinical uses of calcium channel blockers are expanding. In addition to the established uses in patients with arrhythmias, angina pectoris or hypertension, newer and to some extent investigational uses indicate widespread application. For instance, their use has been reported in hypertrophic cardio-myopathy and cold cardioplegia, as well as in pulmonary hypertension, antiplatelet therapy, asthma, achalasia and oesophageal spasm, increased intraocular pressure and in cerebral vasospasm. Their use in obstetrical practice has been proposed. Thus, the presentation of a patient who is treated with calcium channel blockers and who requires anaesthesia will become more common.
Calcium channel blockers may, under certain cirumstances, potentiate haemodynamic and MAC depressive effects of inhalation agents. There is also evidence that the effects of neuromuscular blocking agents may be potentiated. The anaesthetist should be aware that the potential for interactions exists with digoxin, Propranolol, quinidine, theophylline or dantrolene.
Of interest and some significance are the anaesthetic implications of pathophysiological alterations that can be induced by calcium channel blockers, by affecting lower oesophageal tone, intracranial hypertension, bronchomotor tone (asthma), muscular dystrophy, neuromuscular function, hypoxic pulmonary vasoconstriction, malignant hyperthermia, inhibition of platelet aggregation and hyperkalemia.
Despite these significant potential anaesthetic implications and because, at this time, in some instances withdrawal has clearly demonstrated increase in the signs of myocardial ischaemia, it would not seem necessary to recommend preoperative discontinuation of calcium channel blocker medication in patients presenting for anaesthesia. It is, however, appropriate that there is a high index of awareness of potential problems, unless there is some modification in inhalation anaesthetic concentrations and neuromuscular blocker dosage. Monitoring of cardiovascular and neuromuscular functions is essential.
Calcium channel blockers would appear to be currently the drugs of choice for angina pectoris, arrhythmias or hypertension in patients with associated chronic obstructive pulmonary disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Merin RG. Pharmacologie therapy in cardiac patients: calcium channel and beta-adrenergic blocking drugs. American Society of Anesthesiologists Refresher Course Lectures. 1984; 212.
Reaves JG, Kissin I, hell WA, Tosone S. Calcium entry blockers: uses and implications for anesthesiologists. Anesthesiology 1983; 57:504–18.
Merin RG. Slow channel inhibitors, anesthetics and cardiovascular function (Editorial). Anesthesiology 1981; 55:198–200.
Opie LH. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review. Quart J Med 1984; 209:1–16.
Jones RM. Calcium antagonists (Editorial). Anaesthesia 1984; 39:747–9.
Mizgala HF. The calcium channel blockers: pharmacology and clinical applications. Can Anaesth Soc J 1983; 30: S5:10.
Kraynack BJ. Calcium channel blocking agents: side effects and drug interactions. American Society of Anesthesiologists Refresher Course Lectures 1983; 238.
Britt BA. Diltiazem: a review. Can Anaesth Soc J 1985; 32:30–45.
Lee TH, DiSesa VJ, Cohn LH, Lilly LS, Amman EM. Correction of intraoperative diastolic myocardial dysfunction with nifedipine. Clin Cardiol 1983; 6:549–52.
Hicks GL, Salley RK, DeWeese JA. Calcium channel blockers: an intraoperative and postoperative trial in women. Ann Thorac Surg 1984; 37:319–23.
Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304:1582–5.
Kennedy TP, Michael JR, Huang CK et al. Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 129:544–51.
Han P, Boatwright C, Ardlie NG. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with Verapamil. Thromb Haemostas 1983; 50:513–7.
Svedmyr K, Lofdahl CG, Svedmyr N. Nifedipine - a calcium channel blocker - in asthmatic patients. Allergy 1984; 39:17–22.
Patel KR. Calcium antagonists in exercise-induced asthma. Br Med J 1981; 282:932–3.
Becker BS, Burakoff R. Effect of Verapamil on the lower esophageal spincter pressure in normal subjects and in achalasia. Am J Gastroenterol 1983; 78:773–5.
Bortolotti M, Labo G. Clinical and manometic effects of nifedipine in patients with esophageal achalasia. Am J Gastroenterol 1981; 80:39–44.
Blackwell JN, Holt S, Heading RC. Effect of nifedipine on oesophageal motility and gastric emptying. Digestion 1981; 21:50–6.
Monica ML, Hesse RJ, Messerli FH. The effect of a calcium channel blocking agent on intraocular pressure. Am J Ophthal 1983; 96:814.
Pourrai JP andDouste-Blazy P. Renal side effect of nifedipine. Clin Cardiol 1984; 7:29–30.
Schulte-Sasse U, Hess W, Markschies-Hornung A, Tarnow J. Combined effects of halothane anaesthesia and Verapamil on systemic hemodynamics and left ventricular myocardial contractitlity in patients with ischémie heart disease. Anesth Analg 1984;63:7691–8.
Kapur PA, Flacke WE. Epinephrine-induced arrhythmias and cardiovascular function after Verapamil during halothane anaesthesia in the dog. Anesthesiology 1981; 55:218–25.
Lawson NW, Kraynack BJ, Gintautas J. Neuromuscular and electrocardiographs responses to Verapamil in dogs. Anesth Analg 1983; 62:50–4.
Kraynack BJ, Lawson NW, Gintautas J. Neuromuscular blocking action of Verapamil in cats. Can Anaesth Soc J 1983; 30:242–7.
Kapur PA, Bloor BC, Flacke WE, Olewine SK. Comparison of cardiovascular responses to Verapamil during enflurane, isoflurane or halothane anesthesia in the dog. Anesthesiology 1984; 61:156–60.
Maze M, Mason DM. Verapamil decreases the MAC for halothane in dogs. Anesth Analg 1983; 62:274.
Bikhazi GB, Leung I, Foldes FF. Interaction of neuromuscular blocking agents with calcium channel blockers. Anesthesiology 1982; 57; A268.
Kraynack BJ, Lawson NW, Gintautas J, Tjay HT. Effects of Verapamil on indirect muscle twitch responses. Anesth Analg 1983; 62:827–30.
Durant NN, Nguyen N, Briscoe JR, Katz RL. Poten-tiation of pancuronium and succinylcholine by Verapamil. Anesthesiology 1982; 57:A267.
Durant NN, Nguyen N, Katz RL. Potentiation of neuromuscular blockade by Verapamil. Anesthesiology 1984; 60:298–303.
Carpenter RL, Mulroy MF. Edrophonium antagonizes combined verapamil-pancuronium neuromuscular blockade. Anesthesiology 1983; 59:A272.
Zalman F, Perloff JK, Durant NN, Campion DS. Acute respiratory failure following intravenous Verapamil in Duchenne’ s muscular dystrophy. Am Heart J 1983; 105:510–1.
van Poorten JF Dhasmana KM, Kuypers RS, Erdmann W. Verapamil and reversal of vecuronium neuromuscular blockade. Anesth Analg 1984; 63:155–7.
Pederson KE, Thayssen P, Klitgaard NA, Christiansen BD, Nielsen-Kudsk F. Influence of Verapamil on the inotropism and pharmacokinetics of digoxin. Eur J Clin Pharmacol 1983; 25:199–206.
Lander R. Verapamil/beta-blocker interaction: a review. Missouri Med 1983; 80:626–9.
Kieval J, Kirsten EB, Kessler KM, Mallon SM, Myerburg RJ. The effects of intravenous Verapamil on hemodynamic status of patients with coronary artery disease receiving propanolol. Circulation 1982; 65:653–9.
Oesterle SN, Schroeder JS. Editorial: Calcium entry blockade, beta-adrenergic blockade and the reflex control of circulation. Circulation 1982; 65:669–70.
Packer M, Melier J, Medina N et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982; 65:660–8.
Leon MB, Rosing DR, Bonow RO, Lipson LC, Epstein SE. Clinical efficacy of Verapamil alone and combined with Propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981; 48:131–9.
Green JA, Clementi WA, Porter C, Stigelman W. Nifedipine-quinidine interaction. Clin Pharm 1983; 2:461–5.
Burnakis TG, Seldon M, Czaplicki AD. Increased serum theophylline concentrations secondary to oral Verapamil. Clin Pharm 1983; 2:458–61.
Parrillo SJ, Venditto DO. Elevated theophylline blood levels from institution of nifedipine therapy. Ann Emerg Med 1984; 13:216–7.
Saltzman LS, Kates RA, Corke BC, Norfleet EA, Heath KR. Hyperkalemia and cardiovascular collapse after Verapamil and dantrolene administration in swine. Anesth Analg 1984; 63:473–8.
Durbin CG, Fisher NA, Lynch III C. Cardiovascular effects in dogs of intravenous dantrolene alone and in the presence of Verapamil. Anesthesiology 1983; 59:A227.
Bedford RF, Dacey R, Winn HR, Lynch III C. Adverse impact of a calcium entry-blocker (verapamil) on intracranial pressure in patients with brain tumors. J Neurosurg 1983; 59:800–2.
Giffin JP, Cottrell JE, Hartung J, Shwiry B. Intracranial pressure during nifedipine-induced hypotension. Anesth Analg 1983; 62:1078–80.
Rogers MC, Hamburger C, Orven K, Epstein MH. Intracranial présure in the cat during nitroglycerin-induced hypotension. Anesthesiology 1979; 51:227–9.
Marsh ML, Shapiro HM, Smith RW, Marshall LF. Changes in neurologic status and intracranial pressure associated with sodium nitroprusside administration. Anesthesiology 1979; 51:336–8.
Williams DO, Barnes PJ, Vickers HP, Rudolf M. Effects of nifedipine on bronchomotor tone and histamine reactivity in asthma. Br Med J 1981; 283–348.
Zukaitis MG, Hoech GP, Williams CH, Simpson S. Verapamil attenuation of the malignant hyper-thermia syndrome in susceptible pigs. Anesthesiology 1982; 57:A228.
Nugent M, Tinker JH, Moyer TP. Verapamil worsens rate of development and hemodynamic effects of acute hyperkalemia in halothaneanesthetized dogs: effects of calcium therapy. Anesthesiology 1984; 60:435–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jenkins, L.C., Scoates, P.J. Anaesthetic implications of calcium channel blockers. Can Anaesth Soc J 32, 436–447 (1985). https://doi.org/10.1007/BF03011359
Issue Date:
DOI: https://doi.org/10.1007/BF03011359